- Home
- TTD vs INSM Comparison
TTD vs INSM Comparison
Compare TTD & INSM Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- TTD
- INSM
- Stock Information
- Founded
- TTD 2009
- INSM 1988
- Country
- TTD United States
- INSM United States
- Employees
- TTD N/A
- INSM N/A
- Industry
- TTD Computer Software: Programming Data Processing
- INSM Biotechnology: Pharmaceutical Preparations
- Sector
- TTD Technology
- INSM Health Care
- Exchange
- TTD Nasdaq
- INSM Nasdaq
- Market Cap
- TTD 26.5B
- INSM 26.0B
- IPO Year
- TTD 2016
- INSM 2000
- Fundamental
- Price
- TTD $54.66
- INSM $136.10
- Analyst Decision
- TTD Buy
- INSM Strong Buy
- Analyst Count
- TTD 36
- INSM 19
- Target Price
- TTD $92.50
- INSM $139.31
- AVG Volume (30 Days)
- TTD 19.3M
- INSM 3.1M
- Earning Date
- TTD 08-07-2025
- INSM 08-07-2025
- Dividend Yield
- TTD N/A
- INSM N/A
- EPS Growth
- TTD 62.73
- INSM N/A
- EPS
- TTD 0.83
- INSM N/A
- Revenue
- TTD $2,679,088,000.00
- INSM $398,105,000.00
- Revenue This Year
- TTD $18.25
- INSM $32.47
- Revenue Next Year
- TTD $17.36
- INSM $126.03
- P/E Ratio
- TTD $65.88
- INSM N/A
- Revenue Growth
- TTD 23.18
- INSM 21.15
- 52 Week Low
- TTD $42.96
- INSM $60.40
- 52 Week High
- TTD $141.53
- INSM $136.90
- Technical
- Relative Strength Index (RSI)
- TTD 36.25
- INSM 79.64
- Support Level
- TTD $51.93
- INSM $128.02
- Resistance Level
- TTD $55.56
- INSM $136.90
- Average True Range (ATR)
- TTD 2.03
- INSM 3.81
- MACD
- TTD 0.23
- INSM 0.39
- Stochastic Oscillator
- TTD 83.18
- INSM 96.72
About TTD The Trade Desk Inc.
The Trade Desk provides a self-service platform that helps advertisers and ad agencies programmatically find and purchase digital ad inventory (display, video, audio, and social) on devices like computers, smartphones, and connected TVs. It uses data in an iterative manner to optimize the performance of ad impressions purchased. The firm's platform is referred to as a demand-side platform in the digital ad industry, and it generates revenue from fees based on a percentage of what its clients spend on advertising.
About INSM Insmed Incorporated
Insmed Inc is a biopharmaceutical company transforming the lives of patients with serious and rare diseases. The company's first commercial product is ARIKAYCE (amikacin liposome inhalation suspension), approved in the United States for the treatment of Mycobacterium Avium Complex (MAC) lung disease as part of a combination antibacterial drug regimen for adult patients with limited or no alternative treatment options. It is also developing Brensocatib, an oral reversible dipeptidyl peptidase 1 inhibitor for bronchiectasis and other neutrophil-mediated diseases, and Treprostinil Palmitil Inhalation Powder, an inhaled treprostinil prodrug for pulmonary hypertension linked to interstitial lung disease and pulmonary arterial hypertension.